Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 29, 2017
Pharmacy Choice - News - Pharmaceutical Development - March 29, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/29/17 - Acorda Announces Long-Term Safety Data for CVT-301
Acorda Therapeutics, Inc. today announced results from two ongoing, long-term safety studies of CVT-301 in people with Parkinson s that showed no differences in pulmonary function between the group receiving CVT-301 and an observational control group. These results are consistent with previously reported data from Phase 2 b and Phase 3 clinical
3/29/17 - Advanced Urology Associates Announces Designation as a UroLift Center of Excellence Led by Dr. Gregory J. Andros
The designation recognizes that Dr. Andros has demonstrated a commitment to exemplary care for men suffering from urinary tract symptoms and has achieved a high level of training and experience with the UroLift System. Dr. Andros is among the first ten physicians in the nation and the first in the Great Lakes Region to receive a UroLift Center of E
3/29/17 - Ajay Verma, M.D., Ph.D. Joins the Top Ranks of United Neuroscience to Help Tackle Global Neurodegeneration
Dr. Verma joins the United Neuroscience team from Biogen, where he helped spark neurodegeneration therapeutic efforts by building disease area strategy, clinical development teams, experimental medicine capabilities, novel imaging technologies and a neurology drug development fellowship program in conjunction with Massachusetts General Hospital.
3/29/17 - Allergan, Paratek hit late-stage acne goals, prep for sarecycline NDA [Syrian Arab News Agency]
Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for their investigational med sarecycline. The pair will now seek an FDA NDA in the second half of the year after the two replicative late-stage tests that saw the med outdo placebo in treating inflammatory acne lesions in subjects with mode
3/29/17 - AP Top Health News at 2:45 a.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - AP Top Health News at 8:05 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - AP Top Health News at 8:16 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer
ARMO BioSciences, Inc., a clinical-stage immuno-oncology company, announced that the first patient has been dosed in the Company's international Phase 3 pivotal clinical trial to evaluate its lead investigational immuno-oncology drug AM0010 in combination with FOLFOX as second-line treatment for patients with advanced pancreatic cancer.
3/29/17 - AstraZeneca Gets Priority Review By US Of LYNPARZA For Ovarian Cancer
LONDON- AstraZeneca PLC's new drug application for LYNPARZA tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting has been accepted for priority review by the US Food& Drug Administration- with a decision expected in the third quarter 2017.. In clinical trials, LYNPARZA demonstrated a median Progression
3/29/17 - British new lung cancer drug wins approval in China [Philippines News Agency]
The London stock market listed company AstraZeneca Monday announced that the China Food and Drug Administration has granted marketing authorization for its lung cancer pill Tagrisso in China. Tagrisso is designed for the treatment of adult patients with certain genetic mutations, which is the first AstraZeneca medicine approved under the CFDA's...
3/29/17 - Center Point Clinical Services' Studies Show That Pharmacist-led Interventions Increase Clinical Trial Patient Medication Adherence and Compliance and Provide Robust Study Data
Center Point Clinical Services, creator of the world's first Siteless CRO platform, announced today study results presented in two separate posters at the Academy of Managed Care Pharmacy,# AMCP2017, Managed Care and Specialty Pharmacy annual meeting in Denver, Colorado. Joe Martinez, CEO of Center Point Clinical Services and the lead author of bot
3/29/17 - DaVita Clinical Research Wins 2017 CRO Leadership Awards
DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development, has been recognized by Life Science Leader in multiple award categories of its 2017 CRO Leadership Awards. "DCR is devoted to its customers and committed to becoming the service provider of choice," said A
3/29/17 - DrugDev Continues Robust Growth in Europe, Attracts Veteran Pharmaceutical Industry Senior Executive George Masoura as Vice President of Business...
DrugDev's global focus and expertise is reflected in its experience working with 85 sponsors and CROs on more than 1,800 clinical trials. With study team and site users in 60 countries, DrugDev leads the industry in geographical scale with US $2 billion paid to sites in 37 currencies, over 17,000 clinical trial agreement contracts successfully nego
3/29/17 - Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
TOKYO, Mar 29, 2017 Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme inhibitor elenbecestat in patients with early Alzheimer's disease. The Phase III clinical trial program for elenbecestat consists of two global
3/29/17 - EU recommends withdrawing drugs approved on unreliable data [Tehran Times (Iran)]
The European Medicines Agency concluded that data from bioequivalence studies conducted by Micro Therapeutic Research Labs at its two sites in Tamil Nadu, between June 2012 and June 2016, are unreliable and cannot be accepted as a basis for marketing authorisation in the EU.
3/29/17 - Failed trial pushes Foamix down 40% [Globes, Tel Aviv, Israel]
March 29 The share of Foamix Pharmaceuticals Ltd., which develops foam-based drugs, yesterday lost 40% of its value, following unsatisfactory results of the company's clinical trials of its leading product, designed to treat acne. Foamix's market cap is now $197 million, The company has $130 million in cash, which it raised in three financing rou
3/29/17 - Failed trial pushes Foamix down 40% [Sudan Tribune]
The share of Foamix Pharmaceuticals Ltd., which develops foam-based drugs, yesterday lost 40% of its value, following unsatisfactory results of the company`s clinical trials of its leading product, designed to treat acne. Foamix`s market cap is now $197 million, The company has $130 million in cash, which it raised in three financing rounds since i
3/29/17 - FDA Approves Genentech's OCREVUS? (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration approved OCREVUS? as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The FDA s approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific a
3/29/17 - FDA approves Roche's OCREVUS? (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis
Basel Roche announced today that the US Food and Drug Administration approved OCREVUS (TM) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. "The FDA's approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific advance with this first-in-clas
3/29/17 - First Drug For 2 Forms Of MS Gets FDA Nod, RTTR Abuzz, VRTX Gains On Trial Data
LONDON- AstraZeneca plc's New Drug Application for LYNPARZA tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting has been accepted for priority review by the FDA- with a decision expected in the third quarter 2017.. Shares of Catalyst Biosciences Inc. soared more than 190% on Tuesday, following the go-a
3/29/17 - Gainers & Losers Of Mar.28: CBIO, AKER, IMMY, HTGM, PAVM...
JERUSALEM- The following are some of the biotech stocks that made their way onto the Day's Gainers& Losers' list of March 28, 2017. Accordingly, Catalyst's collaborator, ISU Abxis, plans to initiate a phase 1/ 2 proof-of-concept study in individuals with severe hemophilia B in the second quarter of 2017.. After phase 1/ 2 study, ISU Abxis has an op
3/29/17 - Global Anatomic Pathology Market is Growing Rapidly and Expected to Reach Approximately USD 22 billion by 2022
PUNE, MAHARASHTRA, INDIA, March 29, 2017/ EINPresswire.com/ Global Anatomic pathology market is growing rapidly post 2016 as the market is boosted due to ageing population and high investment by government in R&D and anatomic pathology market. Market Highlights The global Anatomic Pathology Market has been evaluated as growing market and expected
3/29/17 - Integron and Stefanini Partner to Deliver Enterprise IoT Solutions to the Healthcare and Pharmaceutical Industry
Integron, a leading provider of managed services for the Internet of Things industry, today announced it is partnering with Stefanini to provide enterprise IoT and outsourcing solutions to the healthcare and pharmaceutical industries. The Internet of Things has enormous potential in the healthcare industry. "We are excited to be partnering with St
3/29/17 - JHL Doses First Patient In JHL1101 Phase I European Trial
About JHL Biotech JHL Biotech Inc. is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL Biotech's mission is to provide the world with low-cost medicines of exceptional quality. JHL Biotech has two world-class facilities built in accordance with United States,.
3/29/17 - MetrioPharm Announces Positive Top-Line Results from a Phase IIa Study in Moderate-to-Severe Psoriasis with its Oral Lead Compound MP1032
By a News Reporter-Staff News Editor at Biotech Week MetrioPharm AG, a biotech company developing small molecule immune modulators for autoimmune and other inflammatory diseases, announces positive top-line results from its phase IIa trial with its proprietary drug compound MP1032 in patients with moderate-to-severe plaque psoriasis.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415